BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers Symposium

Core Insights - BullFrog AI Holdings, Inc. announced the acceptance of an abstract for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, highlighting the company's advancements in AI-driven precision oncology [1][2] - The study focuses on identifying patient subtypes that may respond better to glufosfamide, an investigational drug for pancreatic cancer, utilizing BullFrog AI's proprietary platforms [3][4] Company Overview - BullFrog AI is a technology-enabled drug development company that employs artificial intelligence and machine learning to enhance pharmaceutical and biologic development [1][5] - The company collaborates with leading research institutions to analyze complex biological data, aiming to improve drug discovery and reduce clinical trial failure rates [5] Collaboration and Research - The research was co-authored by experts from Moffitt Cancer Center and Eleison Pharmaceuticals, emphasizing the collaborative nature of the study [3] - The abstract titled "Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma" will be presented during the symposium and published in the Journal of Clinical Oncology [2][4] Industry Impact - The acceptance of the abstract by ASCO signifies the increasing recognition of AI's transformative potential in oncology research [4] - The study aims to provide insights that could lead to more precise and effective treatment strategies for challenging cancers like pancreatic adenocarcinoma [4]